Cargando…

A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wreaked havoc all over the world. Although vaccines for the disease have recently become available and started to be administered to the population in various countries, there i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jo, Seri, Signorile, Luca, Kim, Suwon, Kim, Mi-Sun, Huertas, Oscar, Insa, Raúl, Reig, Núria, Shin, Dong Hae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224295/ https://www.ncbi.nlm.nih.gov/pubmed/35742913 http://dx.doi.org/10.3390/ijms23126468

Ejemplares similares

Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro
por: Jo, Seri, et al.
Publicado: (2020)

Inhibition of African swine fever virus protease by myricetin and myricitrin
por: Jo, Seri, et al.
Publicado: (2020)

Inhibition of SARS-CoV 3CL protease by flavonoids
por: Jo, Seri, et al.
Publicado: (2019)

Dimerization Tendency of 3CLpros of Human Coronaviruses Based on the X-ray Crystal Structure of the Catalytic Domain of SARS-CoV-2 3CLpro
por: Jo, Seri, et al.
Publicado: (2022)

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
por: Kuang, Yi, et al.
Publicado: (2023)

TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19
por: Ansari, Mohammad Azam, et al.
Publicado: (2020)

GTP Preference of d-Glycero-α-d-manno-Heptose-1-Phosphate Guanylyltransferase from Yersinia pseudotuberculosis
por: Kim, Suwon, et al.
Publicado: (2019)

A study of Rose Bengal against a 2-keto-3-deoxy-d-manno-octulosonate cytidylyltransferase as an antibiotic candidate
por: Kim, Suwon, et al.
Publicado: (2020)

A study of inhibitors of d-glycero-β-d-manno-heptose-1-phosphate adenylyltransferase from Burkholderia pseudomallei as a potential antibiotic target
por: Kim, Suwon, et al.
Publicado: (2021)

560. Repurposing Eravacycline for the Treatment of SARS-CoV-2 Infections
por: Reig, Núria, et al.
Publicado: (2020)

A Study of 3CLpros as Promising Targets against SARS-CoV and SARS-CoV-2
por: Jo, Seri, et al.
Publicado: (2021)

Dual inhibition of COVID-19 spike glycoprotein and main protease 3CLpro by Withanone from Withania somnifera
por: Patil, Vishal Shivalingappa, et al.
Publicado: (2021)

The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper
por: Belenkaya, Svetlana V., et al.
Publicado: (2023)

Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2
por: Ferreira, Juliana C., et al.
Publicado: (2020)

Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS‐CoV‐2 protease 3CLpro
por: Ferreira, Juliana C., et al.
Publicado: (2021)

Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2
por: Ferreira, Juliana C., et al.
Publicado: (2022)

Corrigendum: The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper
por: Belenkaya, Svetlana V., et al.
Publicado: (2023)

A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro)
por: Rothan, Hussin A., et al.
Publicado: (2021)

Impact of Drug Repurposing on SARS-Cov-2 Main Protease
por: Ndagi, Umar, et al.
Publicado: (2023)

Rutin Is a Low Micromolar Inhibitor of SARS-CoV-2 Main Protease 3CLpro: Implications for Drug Design of Quercetin Analogs
por: Rizzuti, Bruno, et al.
Publicado: (2021)

Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach
por: Gupta, Yash, et al.
Publicado: (2021)

Multistep rational molecular design and combined docking for discovery of novel classes of inhibitors of SARS-CoV-2 main protease 3CLpro
por: Tumskiy, Roman S., et al.
Publicado: (2021)

Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus
por: Hartini, Yustina, et al.
Publicado: (2021)

Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease
por: Pinzi, Luca, et al.
Publicado: (2021)

Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L
por: Costanzi, Elisa, et al.
Publicado: (2021)

Screening marine algae metabolites as high-affinity inhibitors of SARS-CoV-2 main protease (3CLpro): an in silico analysis to identify novel drug candidates to combat COVID-19 pandemic
por: Muteeb, Ghazala, et al.
Publicado: (2020)

A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study
por: Novak, Jurica, et al.
Publicado: (2022)

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease
por: Baker, Jeremy D., et al.
Publicado: (2021)

Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19
por: Jain, Rashi, et al.
Publicado: (2020)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach
por: Molavi, Zahra, et al.
Publicado: (2021)

In Silico Identification of Potential Inhibitors of the SARS-CoV-2 Main Protease among a PubChem Database of Avian Infectious Bronchitis Virus 3CLPro Inhibitors
por: Soulère, Laurent, et al.
Publicado: (2023)

Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study
por: Baby, Krishnaprasad, et al.
Publicado: (2021)

Thermodynamic and structural insights into the repurposing of drugs that bind to SARS-CoV-2 main protease
por: Wan, Shunzhou, et al.
Publicado: (2021)

Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease
por: Yang, Kai S., et al.
Publicado: (2022)

Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study
por: Refaey, Rana H., et al.
Publicado: (2021)

Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening
por: Sanachai, Kamonpan, et al.
Publicado: (2022)

SARS-CoV-2 main protease targeting potent fluorescent inhibitors: Repurposing thioxanthones
por: BATIBAY, Gönül S., et al.
Publicado: (2023)

Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays
por: Gupta, Yash, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b567m5kh3g0kfvrffgrusfl1h2